Synexus has opened a research center in Bochum.
Synexus has opened a research center in Bochum, which is the company’s fourth in Germany and its 23rd in total. The clinic has moved from a much smaller site in Bochum and is situated in the historic Kortum House. The five hundred square meter clinic runs primary care clinical trials for major clinical research organizations and pharmaceutical companies and provides facilities for up to six professional investigators.
“Germany is one of our foremost locations for running clinical trials with its excellent medical expertise, a history of running clinical trials and a large population,” said Christophe Berthoux, CEO of Synexus. “Europe continues to be a favored region for our clients in the running of their global clinical trials and we are planning to further develop our business in Germany.”
The new clinic, which will be managed by Annette Kuehlenborg, is well placed for easy patient access because it is close to the main station and has parking facilities in the immediate vicinity. The company’s other German centers are in Frankfurt, Berlin, and Leipzig.
“This is a further step in our plan to update and expand our very successful network of clinics across Germany by providing modern clinics which benefit both our patients and our clients in pharma,” noted German Managing Director Christoph Dietrich. “Our success in bringing clinical trials to Germany is dependent on our ability to deliver patients and quality data. We have now put in place a sophisticated patient engagement program which improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”
All of Synexus’ 26 clinics across Europe and Africa focus particularly on undertaking cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.
Read the full release here.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.